Brokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Price Target at $8.00

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has received an average rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $8.00.

Several brokerages have recently issued reports on MIST. Wall Street Zen upgraded Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday. Wells Fargo & Company raised their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Monday, December 15th. HC Wainwright upped their price target on shares of Milestone Pharmaceuticals from $5.00 to $8.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th.

Milestone Pharmaceuticals Stock Down 3.7%

Milestone Pharmaceuticals stock opened at $2.07 on Friday. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $3.06. The stock has a market cap of $176.30 million, a price-to-earnings ratio of -2.52 and a beta of 0.40. The company’s 50-day moving average price is $2.19 and its two-hundred day moving average price is $1.93. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. On average, analysts expect that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in MIST. Propel Bio Management LLC lifted its position in shares of Milestone Pharmaceuticals by 186.1% during the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after acquiring an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth $6,444,000. Simplify Asset Management Inc. raised its position in shares of Milestone Pharmaceuticals by 186.2% during the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after purchasing an additional 1,842,974 shares during the period. Pathstone Holdings LLC purchased a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at $2,000,000. Finally, Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at $1,333,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.